Breathe in protection: inhaled COVID vaccine trial launches

NCT ID NCT06381739

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new COVID-19 vaccine that you breathe in as a mist, instead of getting a shot. It aims to see if it is safe and creates a strong immune response in the lungs and blood. About 350 healthy adults who have already had three mRNA COVID vaccines will receive either the experimental vaccine or a placebo. Researchers will monitor them for 24 weeks to track side effects and immune reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ChAd-triCoV/Mac (a viral-vector vaccine)
What this could lead to: If successful, this could lead to a needle-free COVID-19 vaccine that boosts lung immunity and may offer better protection against infection.
What could go wrong: This is a phase 2 trial with only 350 participants, so results may not apply to everyone. The vaccine is still experimental, and side effects or limited effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 INFECTION

Contacts and locations

Locations

Canadian Center for Vaccinology, Dalhousie University
RECRUITING

Halifax, Nova Scotia, B3K 6R8, Canada
Health Sciences Centre
RECRUITING

Hamilton, Ontario, L8S 4K1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.